As indicated by BLI and survival analysis, sg-p53 AML did not respond to tamoxifen, whereas the same treatment promoted regression of sg-scr leukemia and resulted in a strong survival benefit (median survival 37 and 95 days, respectively) (Fig. 3c and d). The gene discussed is TP53; the disease is acute myeloid leukemia.